13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001931118
Total reported value
$158.4M
$158.4M
27 檔
37.8%
During the Q3 2024 filing period, Superstring Capital Management LP (CIK: 0001931118) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $158.4M across 27 reported positions.
During Q3 2024, Superstring Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 15.36% | -1.84% | +237.83% | |
| 2 | CYTK | Cytokinetics Inc | Stock-Healthcare | 9.97% | — | +15.01% | |
| 3 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 9.84% | — | +40.98% | |
| 4 | GPCR | Structure Therapeutics Inc | Stock-Other | 8.72% | — | — | |
| 5 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 8.52% | +1.74% | — | |
| 6 | TIL | Instil Bio Inc | Stock-Other | 6.34% | — | — | |
| 7 | NVCR | NovoCure Limited | Stock-Healthcare | 5.37% | — | +487.08% | |
| 8 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.05% | — | +3.11% | |
| 9 | FATE | Fate Therapeutics Inc | Stock-Other | 4.49% | — | +194.94% | |
| 10 | CAPR | Capricor Therapeutics Inc | Stock-Other | 4.49% | — | — | |
| 11 | TNGX | Tango Therapeutics Inc | Stock-Other | 4.04% | — | +418.34% | |
| 12 | ETNBGBP | 89bio Inc | Stock-Other | 3.86% | — | -12.52% | |
| 13 | NKTX | Nkarta Inc | Stock-Other | 2.93% | — | -15.49% | |
| 14 | LEGN | Legend Biotech Corp-adr | Stock-Other | 2.58% | — | -60.87% | |
| 15 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.65% | — | — | |
| 16 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.17% | — | -30.70% | |
| 17 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.96% | — | -18.18% | |
| 18 | SVRA | Savara Inc | Stock-Other | 0.74% | -2.39% | — | |
| 19 | BMEA | Biomea Fusion Inc | Stock-Other | 0.74% | -0.22% | -50.00% | |
| 20 | TRML | Tourmaline Bio Inc | Stock-Other | 0.65% | — | -69.44% | |
| 21 | ✓ | Zura Bio LTD | Stock-Other | 0.56% | — | — | |
| 22 | CABA | Cabaletta Bio Inc | Stock-Other | 0.54% | +0.15% | -5.79% | |
| 23 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.46% | — | -55.02% | |
| 24 | IMVT | Immunovant Inc | Stock-Other | 0.31% | -1.28% | — | |
| 25 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.31% | -0.60% | EXIT | |
| 26 | ✓ | Stock-Other | 0.19% | — | — | ||
| 27 | CLYM | Climb Bio Inc | Stock-Other | 0.15% | +3.32% | — |
According to official SEC Form 13F filings, Superstring Capital Management LP reported a total U.S. public equity portfolio value of $158.4M across 27 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ZLAB, CYTK, 430) accounted for 37.8% of total reported equity market value during Q3 2024.
During Q3 2024, Superstring Capital Management LP's top holdings by market value included ZLAB (15.4%)、CYTK (10.0%)、430 (9.8%). The largest single position, ZLAB, represented 15.4% of total portfolio value.
In Q3 2024, Superstring Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.